IFN-alpha/beta R2 Antibody (493715) [Unconjugated]

Recombinant Human IFN-beta (Catalog # 8499-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-beta (30 pg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN-alpha / beta R2 Monoclonal Antibody (Catalog # MAB4015). The ND50 is typically 4-20 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 493715
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IFN-alpha/beta R2 Antibody (493715) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived recombinant human IFN‑ alpha / beta R2
  Ile27-Lys243
  Accession # P48551
• Specificity: Detects human IFN‑ alpha / beta R2 in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 4-20 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IFN-alpha/beta R2 Antibody (493715) [Unconjugated]

• beta receptor10
• human interferon alpha
• human interferon alpha/beta receptor
• IFNABR
• IFN-alpha binding protein
• IFN-alpha/beta R2
• IFN-alpha/beta receptor 2
• IFN-alpha-REC
• IFNAR2
• IFN-aR2
• IFNARB
• IFNbR2
• IFN-bR2
• IFN-R
• IFN-R-2
• interferon (alpha, beta and omega) receptor 2
• Interferon alpha binding protein
• interferon alpha/beta receptor 2
• interferon-alpha/beta receptor beta chain
• Type I interferon receptor 2

Background

IFN-alpha / beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). IFN-alpha / beta R2, in association with IFN-alpha / beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta . IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (3, 4). Mature human IFN-alpha / beta R2 consists of a 217 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 251 aa cytoplasmic domain. Alternate splicing generates a secreted isoform that corresponds to the ECD and a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (5, 6). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (7-9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta , while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12). Within the ECD, human IFN-alpha / beta R2 shares 63%, 60%, and 48% aa sequence identity with bovine, mouse, and ovine IFN-alpha / beta R2, respectively.

1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
3. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
4. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
5. Lutfalla, G. et al. (1995) EMBO J. 14:5100.
6. Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
7. Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
8. Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
9. Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
10. Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
11. McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
12. Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IFN-alpha/beta R2 Antibody (MAB4015)(3)

Publications using MAB4015

• Yuan, H;Wu, X;Wu, Q;Chatoff, A;Megill, E;Gao, J;Huang, T;Duan, T;Yang, K;Jin, C;Yuan, F;Wang, S;Zhao, L;Zinn, PO;Abdullah, KG;Zhao, Y;Snyder, NW;Rich, JN; Lysine catabolism reprograms tumour immunity through histone crotonylation Nature 2023-05-17 [PMID: 37198486] (Neutralization, Human, Transgenic Mouse, Xenograft)
• Y Han, L Tan, T Zhou, L Yang, L Carrau, LA Lacko, M Saeed, J Zhu, Z Zhao, BE Nilsson-Pa, FT Lira Neto, C Cahir, AM Giani, JC Chai, Y Li, X Dong, D Moroziewic, NYSCF Glob, D Paull, T Zhang, S Koo, C Tan, R Danziger, Q Ba, L Feng, Z Chen, A Zhong, GJ Wise, JZ Xiang, H Wang, RE Schwartz, BR tenOever, SA Noggle, CM Rice, Q Qi, T Evans, S Chen A human iPSC-array-based GWAS identifies a virus susceptibility locus in the NDUFA4 gene and functional variants Cell Stem Cell, 2022-10-06;29(10):1475-1490.e6. 2022-10-06 [PMID: 36206731] (ICC, Human)
• Baosheng Chen, David M. Alvarado, Micah Iticovici, Nathan S. Kau, Haeseong Park, Parag J. Parikh et al. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer Cancer Immunology Research 4/1/2020 [PMID: 32127391]

Bioinformatics

• Uniprot:
  • P48551(Human)